Holen Sie sich die Stockscreener-App
0.00
100.00%
-54.65
Schlusskurs vom Vortag:
$54.65
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$4.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
0.00
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$57.35
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
0.00 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
VRTX
Vertex Pharmaceuticals Inc
|
440.58 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.27 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
786.97 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
325.48 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.20 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Growth Value: Whats the analyst consensus on Akero Therapeutics Inc2026 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Valuation Update: Is Akero Therapeutics Inc stock influenced by commodity pricesTrade Risk Assessment & Stock Portfolio Risk Management - baoquankhu1.vn
Sentiment Watch: Is Akero Therapeutics Inc backed by strong institutional buying2026 Winners & Losers & Safe Capital Growth Tips - baoquankhu1.vn
What’s Driving The Super Rally In Akero Shares On Thursday Morning? - MSN
Highs Report: Why is Akero Therapeutics Inc stock going downQuarterly Risk Review & Safe Entry Point Alerts - baoquankhu1.vn
Aug Retail: Will Akero Therapeutics Inc outperform the market in YEAR2026 Weekly Recap & Daily Momentum Trading Reports - baoquankhu1.vn
Panic Selling: Can Akero Therapeutics Inc maintain its current growth rate2026 Sector Moves & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Rallies: What is the earnings history of Akero Therapeutics Inc2026 Momentum & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Akero Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 1AKRO | US00973Y1082 - marketscreener.com
HC Wainwright & Co. Downgrades Akero Therapeutics (AKRO) - MSN
Akero Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US00973Y1082 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Signal Recap: How does Akero Therapeutics Inc score in quality rankings2026 Biggest Moves & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-11 23:57:58 - baoquankhu1.vn
Panic Selling: What is Akero Therapeutics Incs revenue forecastWeekly Market Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Treasury Yields: Is Akero Therapeutics Inc stock good for income investorsEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (AKRO) - Stock Traders Daily
Published on: 2026-03-01 05:11:32 - baoquankhu1.vn
Aug Chart Watch: Can Akero Therapeutics Inc maintain sales growthDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Short Covering: Does Akero Therapeutics Inc meet Warren Buffetts criteriaPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Macro Review: Is Akero Therapeutics Inc stock influenced by commodity pricesGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn
AKRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Akero Therapeutics Inc. stock a falling knife or bargain buyRecession Risk & AI Powered Market Trend Analysis - mfd.ru
Resistance Check: Can Akero Therapeutics Inc stock outperform in a bear marketJuly 2025 Selloffs & Precise Buy Zone Identification - baoquankhu1.vn
Merger Talk: Is Akero Therapeutics Inc backed by strong institutional buying2025 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Is Akero Therapeutics Inc. backed by strong institutional buyingJuly 2025 Fed Impact & Stock Market Timing Techniques - mfd.ru
Akero Therapeutics (NASDAQ: AKRO) holder Janus Henderson now at 4.1% - Stock Titan
Weekly Earnings: Does Akero Therapeutics Inc have consistent dividend growthMarket Risk Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Growth Value: Can Solid Biosciences Inc withstand a market correctionMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
RTW Investments exits Akero Therapeutics (AKRO), reporting 0.0% ownership - Stock Titan
Can Akero Therapeutics Inc. maintain its current growth rateJuly 2025 PreEarnings & High Yield Equity Trading Tips - mfd.ru
Pullback Watch: Should you avoid Akero Therapeutics Inc stock right now2025 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
What’s Akero Therapeutics Inc.’s historical returnPortfolio Performance Report & Daily Risk Controlled Trade Plans - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Aug Wrap: Is Akero Therapeutics Inc. stock showing strong momentumPrice Action & Safe Entry Point Alerts - mfd.ru
Can Akero Therapeutics Inc. maintain sales growthCPI Data & Daily Entry Point Trade Alerts - mfd.ru
Analyst Downgrade: Is Akero Therapeutics Inc stock good for income investors2025 Investor Takeaways & High Yield Stock Recommendations - baoquankhu1.vn
TD Cowen Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Is Akero Therapeutics Inc. stock affected by interest rate hikesJuly 2025 WrapUp & AI Powered Market Entry Strategies - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating Growth in Biotechnology with a 3.39% Potential Upside - DirectorsTalk Interviews
Behavioral Patterns of AKRO and Institutional Flows - Stock Traders Daily
Analyst Calls: Is Akero Therapeutics Inc stock showing strong momentumPortfolio Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Movers: Is Akero Therapeutics Inc. stock influenced by commodity prices2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Does Akero Therapeutics Inc. have consistent dividend growth2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Investment Report: Will Akero Therapeutics Inc outperform the market in YEARJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Income Plays: Is INTU a stock for growth or value investorsJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Guidance Update: What is the earnings history of Akero Therapeutics Inc2025 Volume Leaders & Safe Capital Growth Tips - baoquankhu1.vn
(AKRO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Quarterly Trades: How does ProShares Trust ProShares UltraPro Short QQQ perform in inflationary periodsJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
In Vivo’s Deals Of The Year: Cast Your Vote! - Citeline News & Insights
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):